BSD Reports Increasing European Market Penetration by Terumo for Microwave Ablation System
BSD Medical Corporation today reported that Terumo Europe NV (Terumo), a wholly owned subsidiary of Terumo Corporation, has already introduced the MicroThermX ® Microwave Ablation System (MicroThermX) into the major markets in Europe, including Germany, France and Spain.
Terumo has performed numerous clinical procedures throughout Europe, which has led to enhanced clinical acceptance and greater market penetration. The market potential in the 100 countries included in the Terumo contract is in excess of $1 billion in annual sales. As a result of the increased clinical acceptance, Terumo continues to increase their purchases of MicroThermX generators and antennas.
"Terumo has made a substantial investment in commercialization of the MicroThermX, and their market penetration has already exceeded our expectations. There is a critical need for innovative, cost-effective cancer treatment technologies throughout the world due to the increasing cost of health care," said Sam Maravich, Vice President of Sales and Marketing for BSD. "The MicroThermX system is innovative and cost-effective. Our technology allows the clinician to treat multiple types and sizes of tumors with one minimally invasive system, which significantly reduces procedure cost and complexity. The healthcare systems in the majority of European countries are structured to facilitate fast adoption of minimally invasive, efficacious, cost-effective, advanced technology like the MicroThermX."